The impact of kidney function on colorectal cancer patients with localized and regional diseases: An observational study from Taiwan

Chiang, Sum-Fu; Chen, Jinn‐Shiun; Tang, Reiping; Yeh, Chien-Yuh; Hsieh, Pao-Shiu; Tsai, Wen‐Sy; You, Jeng-Fu; Hung, Hsin-Yuan; Lai, Cheng-Chou; Lin, Jr-Rung; Chiang, Jy-Ming

doi:10.4103/ijc.ijc_294_18

Cited by 5 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery plays a crucial role in the treatment of CRC. As the median age is above 65 years at the time of CRC diagnosis in many studies, surgery is often performed in elderly patients with multimorbidities [ 26 , 27 , 28 , 29 ]. It may explain the wide range of complications, including CKD, acute kidney injury or acute kidney disease [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common and mortal disease. Chronic kidney disease (CKD) is the relatively common comorbidity among cancer patients affecting the available therapy and outcomes. However, data on prevalence of CKD in patients with CRC undergoing surgery is limited. The aim of the study was to evaluate the prevalence of CKD in a cohort of 560 consecutive patients with CRC undergoing surgical treatment with curative intent. Neoadjuvant therapy in a form of radiotherapy or radiochemotherapy was administered before the surgery in 67 patients and in 86 patients, respectively. Results: CKD was reported in 10%, diabetes in 25%, and hypertension in 60%, while anemia was reported in 47%. The patients with CKD were more likely to be older and anemic with higher serum CRP, which reflects a general inflammatory state. Relative to patients without this therapy, patients undergoing neoadjuvant radiochemotherapy were older, had significantly lower eGFR and albumin, and higher creatinine, aspartate aminotransferase and INR, before the surgery. All CKD patients, except two, were older than 65 years of age. Conclusions: In order to ensure the best possible outcomes, CKD should be diagnosed and treated appropriately in oncology patients to prevent complications, so they may continue their therapy with the least interruption or discontinuation of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery

et al. 2022

View full text Add to dashboard Cite

show abstract

“…RI is known to adversely affect survival in most malignancies. 17–21 An analysis in patients with 5908 different types of solid tumors evaluating the effect of RI on survival revealed highly important results. 29 The study in question reported that RI was strongly linked to mortality ( p < 0.0001) when the analysis was performed in all types of patients and cancers combined.…”

Section: Discussionmentioning

confidence: 99%

“…The unfavorable effect of renal insufficiency (RI) on prognosis has been previously demonstrated in hepatocellular cancer, 17 renal cell cancer, 18 urothelial carcinoma, 19 , 20 and colorectal cancer. 21 The increased incidence of RI in lung cancer patients has unfavorable effects on chemotherapy options and outcomes. 22 , 23 Erlotinib is a TKI and currently approved for use in advanced NSCLC and pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

Çelik

Samancı

Karadağ

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung cancer. It is important to predict patients who will respond better to erlotinib. We designed this study to investigate the effect of renal insufficiency (RI) on erlotinib treatment outcomes. Methods All patients receiving erlotinib were stratified into 3 groups. Group 1 consisted of non-RI subjects with classical epidermal growth factor receptor (EGFR) mutations, Group 2 consisted of those with RI (Estimated glomerular filtration rate <60 mL/min) and classical EGFR mutations, and Group 3 consisted of those with non-classical EGFR mutations. Results 82 patients were included in the study. Median progression-free survival (PFS) in patients with classical mutation was approximately 6 months shorter in those with RI, although not statistically significant. Median overall survival (OS) in Group 1, 2 and 3 was 34.1 months, 35.2 months, and 15 months, respectively and although not statistically significant, median OS was 20 months shorter in Group 3. Univariate and multivariate cox-regression analysis revealed shorter PFS and OS in males and those with ECOG ≥2 while PFS and OS were longer in those with recurrent lung tumors and generating rash during erlotinib treatment. There was no difference between RI and non-RI patients in terms of adverse events except for fatigue and appetite loss. Conclusions This research showed OS in patients with and without RI was comparable. Although not statistically significant, PFS in patients with classical mutation was approximately 6 months shorter in those with RI patients.

show abstract

Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients with chronic kidney disease

Huang

Chen

et al. 2021

The American Journal of Surgery

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) can increase serum carcinoembryonic antigen (CEA) levels. We thus aimed to evaluate the impact of CKD on CEA prognostic accuracy in colorectal cancer. Methods: Altogether, 429 patients who underwent curative resection for stages IeIII colorectal adenocarcinoma were grouped according to postoperative CEA levels and history of CKD. Results: Three-year disease-free survival (DFS) was higher in patients with normal postoperative CEA (group A, 83.4%) than in those with elevated postoperative CEA (group B, 64.3%) (p < 0.001). CKD patients had higher postoperative CEA levels than non-CKD patients (odds ratio 3.27, 95% confidence interval 1.78 e5.99, p < 0.001). In multivariable analysis, postoperative CEA level was an independent prognostic factor for DFS in non-CKD, but not CKD, patients. Conclusions: CKD can increase postoperative CEA levels in colorectal cancer patients. Elevated postoperative CEA levels were associated with shorter DFS in non-CKD, but not CKD, patients.

show abstract

The impact of kidney function on colorectal cancer patients with localized and regional diseases: An observational study from Taiwan

Cited by 5 publications

References 39 publications

Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery

Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients with chronic kidney disease

Contact Info

Product

Resources

About